NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Allarity securities between May 17, 2022 and July 19, 2024, both dates inclusive (the “Class Period”). ...

Core Viewpoint - Allarity Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business practices and regulatory compliance during the specified class period from May 17, 2022, to July 19, 2024 [1][2]. Group 1: Legal Proceedings - Investors have until November 12, 2024, to file a lead plaintiff motion in the class action lawsuit [1]. - The lawsuit claims that Allarity and its former officers engaged in improper conduct related to the Dovitinib NDA, which has led to increased regulatory scrutiny and potential legal repercussions [2]. Group 2: Company Misconduct - The complaint asserts that the defendants inflated the regulatory prospects of the Dovitinib NDA and downplayed the likelihood of enforcement actions following the investigation into the company's practices [2]. - This misconduct has exposed Allarity to significant legal, financial, and reputational damages [2].

NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or “the Company”) (NASDAQ: ALLR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquire ...

Core Viewpoint - A class action lawsuit has been filed against Allarity Therapeutics, Inc. for allegedly misleading investors regarding the regulatory prospects of its Dovitinib NDA, with claims of improper conduct and increased risk of scrutiny [1]. Group 1: Allegations Against Allarity Therapeutics - The lawsuit alleges that Allarity overstated the regulatory prospects of the Dovitinib NDA [1]. - It is claimed that Allarity and three former officers engaged in illegal or improper conduct related to the Dovitinib NDA and Dovitinib-DRP PMA [1]. - The misconduct reportedly increased the risk of regulatory scrutiny and potential enforcement actions, leading to significant legal and reputational harm [1]. - Following the announcement of an investigation into wrongdoing, Allarity allegedly downplayed the likelihood of enforcement actions resulting from the investigation [1]. - As a result, the company's public statements were deemed materially false and misleading throughout the class period [1]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their applications by November 12, 2024 [2]. - Participation in the case is not required to be eligible for recovery; shareholders can remain absent class members if they choose [2]. Group 3: About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, having recovered over $1 billion for shareholders since its inception in 2002 [3]. - The firm operates on a contingency fee basis, meaning shareholders pay no fees or expenses unless they recover losses [3].

NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR) securities between May 17, 2022 and July 19, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company’s investors under the ...

ATLANTA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and compliance policies, including allegations that: (i) Defendants had overstated the Dovitinib new drug application’s (“NDA”) continued regulatory prospects; (ii) Al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ___________ Commission File Number: 001-41160 ALLARITY THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) | --- | --- | |-- ...

NEW YORK, Aug. 03, 2024 (GLOBE NEWSWIRE) -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Allarity Therapeutics, Inc. (NASDAQ: ALLR) resulting from allegations that Allarity Therapeutics, Inc. may have issued materially misleading business information to the investing public. So what: If you purchased Allarity securities you may be entitled to compensation without payment of any out of pocket fees or costs thro ...

NEW YORK, Aug. 2, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company").The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATIONOn July ...

NEW YORK, July 31, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ: ALLR) ("Allarity" or "the Company"). The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors. PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION On  ...